Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
- STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m.
- 12/05/2023
|
Applied DNA Sciences, Inc. (APDN) Q3 2023 Earnings Call Transcript
- Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q3 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Operator Good day, and welcome to the Applied DNA Sciences Inc. Fiscal Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 08/12/2023
|
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
- STONY BROOK, NY / ACCESSWIRE / August 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended June 30, 2023 after the market close on Thursday, August 10, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m.
- 08/07/2023
|
3 Penny Stocks to Buy Before the Breakout
- Investors tend to have a love-hate relationship with penny stocks. On the one hand, they offer the possibility of fascinating returns, due to the underlying stock's volatility, and the ability to purchase large shares with relatively little capital.
- 07/27/2023
|
Best Penny Stocks to Buy? 5 To Watch With Big News
- Something that has become one of the go-tos for traders is stock market news. That goes for anything from penny stocks to mega-caps like Apple or Tesla.
- 07/13/2023
|
Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
- STONY BROOK, NY / ACCESSWIRE / June 8, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that it has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023. Dr. James A.
- 06/08/2023
|
Applied DNA Sciences, Inc. (APDN) Q2 2023 Earnings Call Transcript
- Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q2 2023 Results Earnings Conference Call May 12, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President and Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim Group Yi Chen - H.C. Wainwright & Co., LLC Operator Hello and welcome to the Applied DNA Sciences Fiscal Second Quarter 2023 Financial Results.
- 05/11/2023
|
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET. Date & Time: Thursday, May 11 @ 4:30 p.m.
- 05/03/2023
|
What Makes Applied DNA Sciences (APDN) a New Buy Stock
- Applied DNA Sciences (APDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 02/15/2023
|
Applied DNA Sciences, Inc. (APDN) Q1 2023 Earnings Call Transcript
- Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2023 Earnings Conference Call February 9, 2023 4:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President and Chief Executive Officer Clay Shorrock - Chief Legal Officer and Executive Director of Business Development Conference Call Participants Jason McCarthy - Maxim Group LLC Yi Chen - H.C. Wainwright & Co, LLC Operator Good afternoon, and welcome to the Applied DNA Sciences' First Quarter Fiscal 2023 Financial Results Conference Call.
- 02/09/2023
|
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
- STONY BROOK, N.Y.--( BUSINESS WIRE )--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023. The Company will host a conference call for the investment community to discuss its results and answer questions at 4:30 p.m. ET.
- 02/02/2023
|
Applied DNA Sciences, Inc. (APDN) Q4 2022 Earnings Call Transcript
- Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q4 2022 Earnings Conference Call December 14, 2022 4:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President and Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright & Co, LLC Jason McCarthy - Maxim Group LLC Operator Good afternoon, and welcome to the Applied DNA Sciences Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call.
- 12/16/2022
|
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
- STONY BROOK, N.Y.--( BUSINESS WIRE )--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.
- 12/12/2022
|
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
- September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
- 10/17/2022
|
Best Penny Stocks To Buy Now That CPI Is Out? 5 For Your Watch List
- Best penny stocks to buy right now? The post Best Penny Stocks To Buy Now That CPI Is Out?
- 10/13/2022
|
Penny Stocks to Buy Right Now? 3 to Watch in Mid-October 2022
- Add these penny stocks to your watchlist right now The post Penny Stocks to Buy Right Now? 3 to Watch in Mid-October 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/11/2022
|
Why Is Applied DNA (APDN) Stock Up 70% Today?
- Source: Connect world / Shutterstock.com Applied DNA (NASDAQ: APDN ) stock is rocketing higher on Monday after the company announced a massive order for its LinearDNA product. LinearDNA is an enzymatic manufacturing platform that produces DNA without risks of bacterial contamination and non-target DNA sequences.
- 10/10/2022
|
3 Hot Penny Stocks To Watch With Big News Today
- Penny stocks with news today: are they a buy or should you avoid them altogether? The post 3 Hot Penny Stocks To Watch With Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/10/2022
|
Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022. Applied DNA's CEO and Chairman of the Board of Directors, Dr. James A. Hayward,
- 09/07/2022
|
Best Penny Stocks To Buy? 4 That Redditors Are Watching Now
- Penny stocks to buy according to Reddit sentiment. The post Best Penny Stocks To Buy?
- 08/31/2022
|
Buying Penny Stocks Right Now? 3 to Watch This Week
- Here's what you need to know about trading penny stocks on August 22nd The post Buying Penny Stocks Right Now? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/22/2022
|
Investing in Penny Stocks in September? 3 Tips
- Check these tips out for investing in penny stocks in September 2022 The post Investing in Penny Stocks in September? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/20/2022
|
4 Penny Stocks To Watch With Bullish Buys From Options Traders
- Penny stocks with unusual options activity today. The post 4 Penny Stocks To Watch With Bullish Buys From Options Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/19/2022
|
Applied DNA (APDN) Stock Jumps on Monkeypox Test News
- Source: Viacheslav Lopatin / Shutterstock.com Applied DNA Sciences (NASDAQ: APDN ) stock is rising higher on Friday after the company sent its monkeypox test to the NYSDOH for approval. According to a press release, Applied DNA's Linea Monkeypox Virus 1.0 Assay is designed to “identify the genetic signature of the Clade II variant of the monkeypox virus that is currently prevalent in the U.S.” Applied DNA is hoping for approval that designates its monkeypox test as an NYSDOH Laboratory Developed Test (LDT).
- 08/19/2022
|
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
- Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.
- 08/17/2022
|
Applied DNA Sciences (APDN) Reports Q3 Loss, Tops Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of 8.33% and 19.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Applied DNA stock surges again, for 4-day gain of more than 870%
- Shares of Applied DNA Sciences Inc. APDN, +9.93% jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test.
- 08/05/2022
|
10 Top Monkeypox Stocks To Watch Right Now
- 10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/04/2022
|
Applied DNA Sciences (APDN) Stock Soars Another 80%
- Molecular technology firm Applied DNA Sciences (NASDAQ: APDN ) — which among its many specialties include polymerase chain reaction (PCR)-based solutions — recently initiated an analytical validation of its PCR test for the monkeypox virus. The test is designed to identify the monkeypox virus' genetic signature.
- 08/03/2022
|
Applied DNA stock soars more than 80% active trading, after quadrupling in the previous session
- Shares of Applied DNA Sciences Inc. APDN, +311.16% shot up 84.0% in premarket trading, after they more than quadrupled in the previous session (up 311.2%) in the wake of the biotechnology company's announcement that it had initiated a validation of a monkeypox virus test. The two day rally comes after the stock tied its record-low close of 68 cents on Aug. 1, after first setting that record low on July 25.
- 08/03/2022
|
Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch
- Here's what you need to know about buying penny stocks today The post Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/03/2022
|
A small biotech firm's stock spiked 425% after giving a positive update on a PCR test for monkeypox
- A step closer to public testing for monkeypox, the update sent trading volume soaring to over 82 million shares, compared to a daily average of 153,000.
- 08/02/2022
|
Applied DNA Sciences blasts more than 350% higher after initiating validation of monkeypox virus test
- Shares of Applied DNA Sciences Inc. APDN, +390.46% skyrocketed 353.7% higher in very volatile trading Tuesday, after the biotechnology company said it initiated validation of a monkeypox virus test. Trading volume spiked to 73.1 million shares, compared with the full-day average of about 256,450 shares.
- 08/02/2022
|
Why Is Applied DNA (APDN) Stock Up 212% Today?
- Source: Zeedign.com / Shutterstock.com Applied DNA (NASDAQ: APDN ) stock is rocketing higher on Tuesday after the company revealed its starting analytical validation of a monkeypox virus test. The new test from Applied DNA has been developed as a NYSDOH Laboratory Developed Test.
- 08/02/2022
|
Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied DNA and its majority-owned biotherapeutics subsidiary, LineaRx Inc., will present data highlighting the advantages of its enzymatically produced linearDNA (linDNA) as an IVT template for mRNA production at the 2nd Annual mRNA-Based Therapeutics Summit on July 26-28, 2022, in Boston, Massachusett
- 07/22/2022
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President & Chief Executive Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Jason McCarty - Maxim Group Jon Salmanson - Cantella Operator Good evening, and welcome to Applied DNA Sciences' Fiscal Second Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.
- 05/13/2022
|
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of 6.67% and 32.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events' sub-page of the
- 05/09/2022
|
Applied DNA to Participate in Fireside Chat at the 34th Annual ROTH Investor Conference
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA to participate in fireside chat at 34th Annual ROTH Investor Conference.
- 03/10/2022
|
New Strong Sell Stocks for February 15th
- ATGE, ALGN, and APDN have been added to the Zacks Rank #5 (Strong Sell) List on February 15, 2022
- 02/15/2022
|
Applied DNA Sciences, Inc.'s (APDN) CEO James Hayward on Q1 2022 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc.'s (APDN) CEO James Hayward on Q1 2022 Results - Earnings Call Transcript
- 02/10/2022
|
Applied DNA Schedules Fiscal 2022 First Quarter Financial Results Conference Call and Webcast for Thursday, February 10, 2022
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA to report FQ1'22 financial results after market close on February 10, 2022, and host an investor call at 4:30 pm ET.
- 02/03/2022
|
Applied DNA Sciences' Q4 Revenues Skyrockets Buoyed By Momentum In COVID-19 Diagnostic Testing
- Applied DNA Sciences Inc (NASDAQ: APDN) reported a more than ninefold Y/Y increase in Q4 FY21 revenues, driven by the rise in clinical laboratory service revenues related to COVID-19 testing. For Q4, the firm reported $3.0 million in revenues, up from $314,000 a year ago, beating the consensus Wall Street estimate of $2.3 million.
- 12/10/2021
|
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -53.13% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 12/10/2021
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2021 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2021 Results - Earnings Call Transcript
- 12/10/2021
|
Applied DNA Sciences: Q4 Earnings Insights
- Applied DNA Sciences (NASDAQ:APDN) reported its Q4 earnings results on Thursday, December 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
- 12/09/2021
|
A Preview Of Applied DNA Sciences's Earnings
- Applied DNA Sciences (NASDAQ:APDN) is set to give its latest quarterly earnings report on Thursday, 2021-12-09. Here's what investors need to know before the announcement.
- 12/08/2021
|
Applied DNA Schedules Fourth Quarter and Full Fiscal Year 2021 Financial Results Conference Call and Webcast for Thursday, December 9, 2021
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA to report fourth quarter and full-year 2021 financial results after market close on December 9, 2021.
- 12/03/2021
|
Applied DNA Sciences (APDN) Stock: Why The Price Is Surging Today
- The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 50% pre-market today. This is why it happened.
- 11/29/2021
|
Applied DNA Stock Surges On Launch Plans For Linea 2.0 COVID-19 Assay For Omicron Variant
- Applied DNA Sciences Inc (NASDAQ:APDN) plans to introduce its Linea 2.0 COVID-19 Assay for the SARS-CoV-2 E and N genes after submitting its validation data to the New York State Department of Health (NYSDOH) in the next few days. The Company also announced that its EUA-authorized Linea COVID-19 Assay Kit likely exhibits a unique double S-gene target failure specific to the Omicron variant.
- 11/29/2021
|
APDN Stock: Why It Significantly Increased
- The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 20% yesterday. This is why it happened.
- 10/13/2021
|
Applied DNA Implements safeCircle™ COVID-19 Testing Program at Sarah Lawrence College
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #covid19--Applied DNA adds Sarah Lawrence College as COVID-19 testing customer.
- 10/12/2021
|
Applied DNA Receives Purchase Orders Totaling $1.6 Million to Tag Textile Fibers
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #supplychainsecurity--Applied DNA Receives Purchase Orders Totaling $1.6M to Tag Textile Fibers; Progressing Textile Projects Representing New Commercial Opportunities
- 09/27/2021
|
5 Cannabis Stocks That Lit Up Wall Street This Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
- 09/10/2021
|
Flora Growth Launches Cannabis Product Validation And Authentication Platform With TruTrace And Applied DNA Sciences
- Flora Growth Corp. (NASDAQ:FLGC) announced Thursday it has signed agreements with TruTrace Technologies, Inc. (CSE:TTT) (OTCQB:TTTSF) and Applied DNA Sciences, Inc. (NASDAQ:APDN) to launch a complete and differentiated global cannabis product validation and authentication platform for consumers, distributors and government regulators. Flora will use TruTrace's blockchain-based SaaS software to track inventory and product quality testing, including molecular tagging through Applied DNA's Certain T platform to track the cannabis flower and derivatives originating from its Cosechemos cultivation and extraction facility.
- 09/08/2021
|
Applied DNA Stock Jumps On New COVID-19 Testing Contract
- Applied DNA Sciences Inc's (NASDAQ:APDN) subsidiary Applied DNA Clinical Labs has been awarded a testing contract by Suffolk County Community College. Also Read: Applied DNA Receives COVID-19 testing contract by the City University of New York
- 09/02/2021
|
Applied DNA Awarded Suffolk County Community College COVID-19 Testing Contract
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA to monitor for the prevalence of COVID-19 among Suffolk County Community College's unvaccinated staff and faculty.
- 09/02/2021
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q3 2021 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q3 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Applied DNA Sciences (APDN) Reports Q3 Loss, Lags Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -91.67% and -50.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Recap: Applied DNA Sciences Q3 Earnings
- Shares of Applied DNA Sciences (NASDAQ:APDN) fell 7.8% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 36.11% year over year to ($0.46), which missed the estimate of ($0.22).
- 08/12/2021
|
Applied DNA Announces Third Quarter Fiscal 2021
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVIDDiagnostics--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the three and nine months ended June 30, 2021. “We delivered excellent year-over-year revenue growth in the fiscal third quarter while laying the groundwork to secure a recently awarded COVID-19 testing services contract that has potential to be th
- 08/12/2021
|
Applied DNA Schedules Fiscal 2021 Third Quarter Financial Results Conference Call and Webcast for Thursday, August 12, 2021
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVIDDiagnostics--Applied DNA Sciences Schedules FQ3'21 Investor Call and Webcast.
- 08/05/2021
|
Why Is Applied DNA Stock Soaring Higher Today?
- Applied DNA Sciences Inc's (NASDAQ:APDN) subsidiary Applied DNA Clinical Labs LLC has received a COVID-19 testing contract by the City University of New York (CUNY) to facilitate the University's reopening in the fall. The contract term is 12 months, has a maximum value not to exceed $35.0 million, and contains no minimum weekly testing commitment.
- 08/03/2021
|
APDN Stock Price Increases Over 33% Intraday: Why It Happened
- The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 33% during intraday trading. This is why it happened.
- 08/03/2021
|
Applied DNA Awarded The City University of New York (CUNY) COVID-19 Testing Contract
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Secures COVID-19 Testing Award From The City University of New York with a Maximum Value of $35.0 Million
- 08/03/2021
|
New Strong Sell Stocks for June 29th
- ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.
- 06/29/2021
|
Applied DNA's Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies Against Three Variants
- Applied DNA Sciences Inc (NASDAQ: APDN) and its program development partner, Evvivax S.R.L., have announced results from an in vitro neutralization study of sera evaluating the company's COVID-19 vaccine in felines.
- 06/07/2021
|
Breaking Down a Busy Week of Weed Stocks
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.
- 06/04/2021
|
Here Are the Cannabis Stocks That Caught Fire This Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.
- 05/14/2021
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2021 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and Press Release Published 12 May 2021
- STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), today clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit (the “Assay Kit”) and certain information contained in its previously disseminated 12 May 2021 press release (the “Press Release”) relating to the U.S. Food and Drug Administration's (FDA) grant of a re-issued Emergency Use Authorization (EUA) that expands the Assa
- 05/13/2021
|
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the three and six months ended March 31, 2021. “We are pleased to deliver a strong fiscal second quarter with year-over-year revenue growth of 384%, capping an impressive first half of the fiscal year distinguished by demand for our COVID-19 diagnostics and surveillance testing offer
- 05/13/2021
|
FDA Grants EUA to Applied DNA LineaTM COVID-19 Assay Kit for Asymptomatic Screening of Individuals with Serial Testing
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Linea™ COVID-19 Assay Kit EUA expanded to include asymptomatic serial screening as an expansion of intended use.
- 05/12/2021
|
APDN Stock: Over 25% Increase Intraday Explanation
- The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 25% during intraday trading. This is why it happened.
- 05/11/2021
|
Applied DNA Receives CLIA Certification, Enabling High Throughput Diagnostic COVID-19 Testing
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Applied DNA Clinical Labs, LLC (ADCL) subsidiary received CLIA (Clinical Laboratory Improvement Amendments) certification from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for COVID-19 testing using EUA-authorized methods and devices. With this certifica
- 05/11/2021
|
Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar'
- 05/07/2021
|
Will Applied DNA Sciences (APDN) Report Negative Q2 Earnings? What You Should Know
- Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2021
|
Applied DNA Shares Slightly Up On New Contract With U.S. Defense Logistics Agency
- Supply chain security provider Applied DNA Sciences, Inc. (NASDAQ:APDN) reported Wednesday it had signed a new contract with the Defense Logistics Agency's (DLA) Land and Maritime's Product Test Center (PTC) with a maximal value of $1.04 million. The indefinite-delivery contract has a five-year performance term.
- 05/05/2021
|
Moving Average Crossover Alert: Applied DNA Sciences (APDN)
- Applied DNA Sciences (APDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- 04/28/2021
|
Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines
- STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #CatHealth--Preliminary results of phase I clinical trial yields high titers of SARS-CoV-2 neutralizing antibodies from all cohort members.
- 04/12/2021
|
Applied DNA Sciences (APDN) Moves 13.2% Higher: Will This Strength Last?
- Applied DNA Sciences (APDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/08/2021
|
Applied DNA Sciences (APDN) Upgraded to Buy: Here's What You Should Know
- Applied DNA Sciences (APDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/07/2021
|
Applied DNA to Participate in Upcoming Conferences
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences. March 9 – 10, 2021 – Dr. James A. Hayward, president and CEO, will present a company overview at the H.C. Wainwright Global Life Sciences Virtual Conference. Dr. Hayward and Beth Jantzen, chief financial officer, will also hold virtual investor meet
- 03/08/2021
|
Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market
- STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #COVID19--If the veterinary vaccine candidate demonstrates effectiveness, the two companies intend to apply to USDA to enable commercial vet sales under APHIS.
- 03/02/2021
|
Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM College
- STONY BROOK, N.Y. & NEW YORK--(BUSINESS WIRE)---- $APDN #COVID19--NYC-based LIM College joins other education institutions relying on Applied DNA's safeCircle service to ensure a safe learning environment.
- 02/19/2021
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q1 2021 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q1 2021 Results - Earnings Call Transcript
- 02/11/2021
|
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -12.73% and 15.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/11/2021
|
Applied DNA Schedules Fiscal 2021 First Quarter Financial Results Conference Call and Webcast for Thursday, February 11, 2021
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar' section of the Company's corporate website and embedded into the live webcast. Conference Call and
- 02/05/2021
|
Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--"Our veterinary vaccine program is a cost- and time-efficient path to commercializing our COVID-19 vaccine development work."
- 02/02/2021
|
Will Applied DNA Sciences (APDN) Report Negative Q1 Earnings? What You Should Know
- Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/28/2021
|
Why Applied DNA Sciences Is Up 30% Today
- Applied DNA Sciences (NASDAQ: APDN) shares are trading higher on reports the U.K. COVID strain could become the dominant strain in the U.S. The FDA last week reported the company's test is sensitive to the U.K. variant.
- 01/15/2021
|
Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ:APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its safeCircle™ pooled surveillance testing service has seen a 158% increase in the daily average number of tests performed to date in January 2021 compared to December 2020. The increase is chiefly the result of the scale-up of certain testing contracts and from the acquisition of new clients. Launched in the fou
- 01/15/2021
|
Applied DNA Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with a group of institutional investors of 1,810,000 shares of common stock at a price of $8.30 per share, priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $15 million, before deducting the placement agent's f
- 01/13/2021
|
Applied DNA Announces Pricing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,810,000 shares of common stock at a price of $8.30 per share, priced at-the-market under Nasdaq rules, in a registered direct offering, resulting in total gross proceeds of approximat
- 01/11/2021
|
Why Applied DNA Sciences Is Up 80% Today
- Applied DNA Sciences (NASDAQ: APDN) shares are trading higher after the U.S. Food and Drug Administration published communication that identifies the company's Linea COVID-19 Assay Kit as one of only two tests marketed under the FDA's Emergency Use Authorization. The tests are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K.
- 01/08/2021
|
U.S. FDA Lists Applied DNA's Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the “Communication”) that identifies the Company's Linea™ COVID-19 Assay Kit (the “Assay Kit”) as one of only two tests marketed under the FDA's Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2
- 01/08/2021
|
Applied DNA Partners with CLEARED4 on Pooled COVID-19 Surveillance Testing Program
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (ADCL) has entered into a reseller and sales referral partnership with CLEARED4, a field-proven, New York-based provider of return-to-work health safety solutions. Under the terms of the partnership, ADCL can resell subscriptions
- 12/29/2020
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2020 Results - Earnings Call Transcript
- Seeking Alpha Transcripts | Healthcare Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2020 Results - Earnings Call Transcript Dec. 17, 2020 10:09 PM ET | | About: Applied DNA Sciences, Inc. (APDN) by: SA Transcripts Subscribers Only Earning Call Audio Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2020 Earnings Conference Call December 17, 2020 4:30 PM ET Corporate Participants Sanjay Hurry - Executive Director of Investor Relations and Corporate Communications James Hayward - Chairman, President and Chief Executive Officer
- 12/17/2020
|
Applied DNA Sciences (APDN) Reports Q4 Loss, Misses Revenue Estimates
- Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -38.98% and -55.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 12/17/2020
|
Recap: Applied DNA Sciences Q4 Earnings
- Shares of Applied DNA Sciences (NASDAQ:APDN) fell 21.15% after the company reported Q4 results. Quarterly Results Earnings per share rose 43.06% year over year to ($0.82), which missed the estimate of ($0.52).
- 12/17/2020
|
Applied DNA Reports 2020 Year End and Fiscal Fourth Quarter Financial Results
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2020. “Our activities in fiscal 2020 were principally devoted to the establishment of our diagnostic and surveillance testing programs for COVID-19 and to further positioning our proprietary LinearDNA™ manufacturin
- 12/17/2020
|
Applied DNA Awarded Pooled Surveillance Testing Contract Valued at Up to $2.0 Million from Suffolk County (N.Y.) Government
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing program (the “Program”) award with a potential value of up to $2.0 million from the Suffolk County (N.Y.) Government (the “County”). The 6-month term and awar
- 12/17/2020
|
Compliance with New York State Winter COVID-19 Plan Drives Demand for Applied DNA's Pooled Surveillance Testing Program
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its Applied DNA Clinical Laboratories, LLC (ADCL) subsidiary is experiencing growing demand for its safeCircle™ pooled COVID-19 surveillance testing program that is being primarily driven by New York State (the “State”) schools moving to comply with the State's Winter COVID-19 Plan (the “Plan”) that al
- 12/11/2020
|
Applied DNA Schedules Fiscal 2020 Fourth Quarter Financial Results Conference Call for Thursday, December 17, 2020 at 4:30 PM EST
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it will release financial results for its fiscal 2020 fourth quarter ended September 30, 2020 after market close on Thursday, December 17, 2020. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Standard Time that will also be broadcast live over th
- 12/08/2020
|
Nutrition21 Transitions to Applied DNA's CertainT® Platform to Secure IP-protected Portfolio of Dietary Supplement Ingredients
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the expansion of commercial activities under its multi-year Master Services Agreement (MSA) with Nutrition21 whereby Nutrition21 has transitioned to Applied DNA's CertainT® platform to secure its IP-protected portfolio of dietary supplement ingredients. Concurrently, the Company received two follow-on
- 12/07/2020
|
Applied DNA to Provide COVID-19 Surveillance Testing to Stony Brook Basketball
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (“ADCL”), will provide its COVID-19 surveillance testing program to the Stony Brook University Seawolves men's and women's basketball teams. ADCL's pooled surveillance testing platform, known as safeCircle™, will aid the safe return to
- 12/01/2020
|
Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotech with expertise in engineered veterinary cancer immunotherapy and targeted vaccines, and Veterinary Oncology Services at Guardian Veterinary Specialists (GVS), a multi-specialty veterinary hospital, announced the receipt of approvals from the New York State Depa
- 11/30/2020
|
Applied DNA to Present at the Imperial Capital 2020 Security Investor Conference on December 3
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it is scheduled to participate virtually in the Imperial Capital 2020 Security Investor Conference on Thursday, December 3, 2020. Dr. James A. Hayward, chief executive officer, will present at 10:45 a.m. EST that day and host one-on-one meetings throughout the day. An archived webcast will be available
- 11/27/2020
|
Applied DNA Significantly Expands Addressable Market for Linea™ COVID-19 Assay Kit via Successful Amendment to FDA EUA
- STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that the U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) amendment that expands the installed base of RT-PCR platforms that can process the Company's Linea™ COVID-19 Assay Kit. The EUA amendment extends the RT-PCR platform authorization from Applied Biosystems' (Therm
- 11/25/2020
|
Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate
- Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
- 09/16/2020
|
'Companies need to step up': The ever-increasing demand for disinfection during the pandemic
- New ways to clean or disinfect buildings, surfaces and clothes are seeing increased demand, according to tech company leaders.
- 08/17/2020
|
Is Applied DNA Sciences (NASDAQ:APDN) Using Too Much Debt?
- The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- 08/17/2020
|
Applied DNA Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing
- Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it has filed a nonprovisional patent application with the United States Patent and Trademark Office (USPTO) entitled "Methods and Systems of PCR-Based Recombinant Adeno-Associated Virus (AAV) Manufacture" (the "Patent"). The Patent claims priority to a previously filed provisional patent application filed with the USPTO in August of 2019.
- 08/17/2020
|
Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging
- Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 14/572,552 (US 2016/0168781 A1) entitled "Method and Device for Marking Fibrous Materials." The allowed claims cover methods of DNA-tagging cotton fibers while they travel through the forced air systems found at cotton gins, and later authenticating the DNA-tagged cotton fibers to prove their provenance and/or authenticity all the way to finished goods. DTS units have tagged over 300 million pounds of cotton to-date.
- 08/12/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
Applied DNA Reports Fiscal Third Quarter 2020 Financial Results
- Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced consolidated financial results for the fiscal third quarter and the nine months ended June 30, 2020.
- 08/06/2020
|
Stocks Showing Market Leadership: Applied Dna Sciences Earns 93 RS Rating
- Applied Dna Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
- 08/05/2020
|
Why Applied DNA Sciences' Stock Is Trading Higher Today
- Applied DNA Sciences, Inc. (NASDAQ: APDN) shares are trading higher after the company announced the FDA granted an Emergency Use Authorization amendment that increases the company's COVID-19 diagnostic kit testing capacity through the use of automated RNA extraction."The company believes the amendment can greatly enhance the efficiency of laboratories across the country who adopt the diagnostic kit while expanding by more than tenfold the target installed base of authorized RT-PCR equipment. To match the potential for higher demand, the company is increasing production of its diagnostic kit," according to the press release.Applied DNA Sciences is a provider of DNA-based supply chain, anti-counterfeiting, and anti-theft technology.Applied DNA's stock was trading up 16% at $10.10 per share on Tuesday at the time of publication. The company has a 52-week high of $19.69 and has a 52-week low of $2.52.See more from Benzinga * Why Kodak's Stock Is Trading Lower Today * Why Overstock Is Trading Higher Today * Why Eastman Kodak's Stock Is Soaring Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/31/2020
|
FDA Approves EUA Amendment Increasing Applied DNA’s COVID-19 Diagnostic Kit Testing Capacity Through Use of Automated RNA Extraction and Expands Supported Platforms
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) amendment that both expands the installed base of PCR equipment platforms that can process the Company’s LineaTM COVID-19 Assay Kit and introduces automation to significantly increase the throughput of the assay by use of robotic RNA extraction.
- 07/31/2020
|
Why Applied DNA Sciences' Stock Is Trading Higher Today
- Applied DNA Sciences, Inc. (NASDAQ: APDN) shares are trading higher after the company announced the FDA granted an Emergency Use Authorization amendment that increases the company...
- 07/31/2020
|
Applied DNA to Report Fiscal 2020 Third Quarter Financial Results After Market Close on August 6, 2020
- Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2020 third quarter financial results after market close on Thursday, August 6, 2020. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. EDT that same day. Presentation slides will also be posted to the Investors section of the Company’s website and embedded into the webcast at that time.
- 07/30/2020
|
Coronavirus updates: Texas governor says Covid-19 not conquered yet; U.S. cases jump by more than 68,000
- The coronavirus has infected more than 15.62 million people around the world as of Friday, killing at least 635,086 people.
- 07/24/2020
|
Signify plans production hike of UV light that breaks down coronavirus particles in seconds
- Signify says scientists at Boston University have "validated" the effectiveness of the company's UV lights in degrading the coronavirus.
- 07/24/2020
|
COVID-19 Impact & Recovery Analysis - Anti-Counterfeit Packaging Market (2020-2024) | Booming E-commerce Industry to Boost Growth | Technavio
|
COVID-19 Impact & Recovery Analysis - Anti-Counterfeit Packaging Market (2020-2024) | Booming E-commerce Industry to Boost Growth | Technavio
- The Global Anti-Counterfeit Packaging Market will grow by $ 105.86 bn during 2020-2024
- 07/22/2020
|
Applied DNA's COVID-19 Vaccine, And Other News: The Good, Bad And Ugly Of Biopharma
- Applied DNA reports positive preclinical results for COVID-19 vaccine. Berkeley Lights shows impressive debut on NASDAQ.
- 07/20/2020
|
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) * AC Immune SA (NASDAQ: ACIU) ( announced clinical trial update for its Alzheimer's vaccine candidate) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Castle Biosciences Inc (NASDAQ: CSTL) * Dynavax Technologies Corporation (NASDAQ: DVAX)(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant) * Heat Biologics Inc (NASDAQ: HTBX) * Novavax, Inc. (NASDAQ: NVAX) * Qiagen NV (NYSE: QGEN)( Thermo Fisher Scientific Inc. (NYSE: TMO) announced a sweetened offer to buy the company) * Quest Diagnostics Inc (NYSE: DGX) * Otonomy Inc (NASDAQ: OTIC) * Principia Biopharma Inc (NASDAQ: PRNB)(reacted to buyout rumors) * Relay Therapeutics Inc (NASDAQ: RLAY) (jumped 75.25% on its debut) * Sanofi SA (NASDAQ: SNY) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia) * TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) * West Pharmaceutical Services Inc. (NYSE: WST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 16) * Avidity Biosciences Inc (NASDAQ: RNA) * Legend Biotech Corp (NASDAQ: LEGN) * Nkarta Inc (NASDAQ: NKTX) (IPOed last Friday) * Repare Therapeutics Inc (NASDAQ: RPTX) * Tricida Inc (NASDAQ: TCDA) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic acidosis treatment candidate)Stocks In Focus PhaseBio Doses First Patient In Potentially Pivotal Trial of PB1046 For COVID-19 PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) said it has dosed the first patient in a potentially pivotal Phase 2 clinical trial, dubbed VANGARD, to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome, or ARDS.PB1046 is a novel, once-weekly, subcutaneously-injected VIP receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems, having anti-inflammatory, antifibrotic and potent bronchodilatory and immunomodulatory effects in the respiratory system.The stock advanced 10.21% to $5.18 in after-hours trading.Applied DNA Reports Positive Preclinical Data For DNA Vaccine Candidates Applied DNA Sciences Inc (NASDAQ: APDN) announced linear-DNA forms of COVID-19 vaccine candidates under development by partner Takis Biotech and manufactured by it yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.In premarket trading Friday, Applied DNA shares were jumping 79.09% to $16.10.Puma Biotech Announces Regulatory Nod For Breast Cancer Drug In MalaysiaPuma Biotechnology Inc (NASDAQ: PBYI) said its licensing partner Specialised Therapeutics Asia has received marketing approval of Nerlynx in Malaysia from the Drug Control Agency, under Malaysia's Ministry of Health.Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy.In after-hours trading, the stock gained 3.89% to $10.15.Nabriva's Community-acquired Pneumonia Drug Approved In Canada Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) said its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous formulations of Xenleta for the treatment of community-acquired pneumonia in adults.The stock jumped 29.76% to $1.09 in after-hours trading.ASLAN to Transfer Primary Listing to Nasdaq ASLAN PHARMACEU/ADR (NASDAQ: ASLN) said it has made further progress toward a primary listing on the Nasdaq and the receipt of a Notice of Delisting from the Taipei Exchange, in an expected step in the TPEx delisting process.The company also said it will retain its listing of ADSs on Nasdaq and existing holders of ADS do not need to take any action as a result of this announcement.On The Radar IPOs Pandion Therapeutics, Inc., a clinical-stage biotech developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune disease, said it has priced its upsized initial public offering, or IPO, of 7.5 million shares at $18 per share to raise gross proceeds of $135 million. The company earlier estimated the pricing to be between $16 and $18. The shares will begin trading on the Nasdaq under the ticker symbol PAND.LX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, priced its IPO of 8.5 million shares at $19 per share compared to the estimated price range of $15-$17.The company expects to raise gross proceeds of $161.5 million from the offering. The shares will begin trading on the Nasdaq under the ticker symbol ALXO.Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, priced its global offering of an aggregate of 11 million shares. The offering is expected to raise gross proceeds of $74.3 million.See more from Benzinga * The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent * The Daily Biotech Pulse: Blueprint, Roche Ink .7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/17/2020
|
Applied DNA and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that linear-DNA forms of COVID-19 vaccine candidates under development by partner Takis Biotech ("Takis") and manufactured by the Company yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.
- 07/17/2020
|
Applied DNA and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19
- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that ena
- 07/17/2020
|
Applied DNA Appoints New Head of Investor Relations and Corporate Communications
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the appointment of Mr. Sanjay Hurry to Executive Director of Investor Relations and Corporate Communications for the company. In this role, Mr. Hurry will oversee the Company’s outreach with the investment community and report to Dr. James A. Hayward, Chairman, President, and Chief Executive Officer.
- 07/15/2020
|
Applied DNA Appoints New Head of Investor Relations and Corporate Communications
- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that ena
- 07/15/2020
|
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) * Akero Therapeutics Inc (NASDAQ: AKRO) * Altimmune Inc (NASDAQ: ALT) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * AMRYT PHARMA PL/S ADR (NASDAQ: AMYT) (reacted to its ADSs commencing trading on the Nasdaq) * argenx SE - ADR (NASDAQ: ARGX) * Assembly Biosciences Inc (NASDAQ: ASMB) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Crispr Therapeutics AG (NASDAQ: CRSP) * Cytokinetics, Inc. (NASDAQ: CYTK) * Eli Lilly And Co (NYSE: LLY) * Emergent Biosolutions Inc (NYSE: EBS) * GENMAB A/S/S ADR (NASDAQ: GMAB) * GenMark Diagnostics, Inc (NASDAQ: GNMK) (pre-announced above-consensus Q2 revenue) * Immunomedics, Inc. (NASDAQ: IMMU) * Intellia Therapeutics Inc (NASDAQ: NTLA) * MacroGenics Inc (NASDAQ: MGNX) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Nantkwest Inc (NASDAQ: NK) * NeoGenomics, Inc. (NASDAQ: NEO) * Opko Health Inc. (NASDAQ: OPK) * Pacira Biosciences Inc (NASDAQ: PCRX) * Quidel Corporation (NASDAQ: QDEL) * Seres Therapeutics Inc (NASDAQ: MCRB) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) * TG Therapeutics Inc common stock (NASDAQ: TGTX) (announced publication of pre-clinical data on its umbralisib) * Twist Bioscience Corp (NASDAQ: TWST) - announced a partnership with Takeda Pharmaceutical Co Ltd (NYSE: TAK) for expanding biologics discovery * VBI Vaccines Inc (NASDAQ: VBIV) * Zai Lab Ltd (NASDAQ: ZLAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) * Brickell Biotech Inc (NASDAQ: BBI) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Polypid Ltd (NASDAQ: PYPD) * VIVUS, Inc. (NASDAQ: VVUS) (announced Chapter 11 filing and plan for being taken over by its creditorStocks In Focus Biogen Announces Publication Of Positive Phase 1/2 Data For Neurodegenerative Disease Drug Biogen Inc (NASDAQ: BIIB) announced publication in the New England Journal of Medicine positive results from a Phase 1/2 study of tofersen for the potential treatment of superoxide dismutase 1, or SOD 1, amyotrophic lateral sclerosis, or ALS. A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately 2% of all ALS cases, the company said.OptiNose Announces Co-Promotion Agreement For Nasal Spray In US OptiNose Inc (NASDAQ: OPTN) announced an agreement with kaleo, a pharmaceutical company, to co-promote Xhance exhalation nasal spray 93 mcg for the treatment of nasal polyps in patients 18 and older in the U.S.Under the terms of the agreement, kaleo will promote Xhance to an agreed-upon audience of office-based health care professionals, rapidly increasing promotional reach and frequency.The stock was up 16.71% at $4.96 premarket Thursday.Anaptys Bio's Rare Psoriasis Drug Gets Orphan Drug Designation AnaptysBio Inc (NASDAQ: ANAB) said the FDA has granted orphan drug designation for imsidolimab, its proprietary anti-interleukin-36 receptor antibody, for the treatment of patients with generalized pustular psoriasis.The company said it expects to release additional data and regulatory strategy update from the Phase 2 GALLOP trial that is evaluating imsidolimab in the second half of 2020.The company plans to expand clinical development of the investigational compound to additional indications in the second half of 2020. It also said it expects to release top-line data from the Phase 2 POPLAR trial in palmoplantar pustulosis in the second half of 2020.The stock rose 14.15% to $25.98 in after-hours trading.See also: The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus Applied DNA Creates COVID-19 Testing Subsidiary, Receives Approval For EUA Amendment Applied DNA Sciences Inc (NASDAQ: APDN) announced the formation of a wholly owned subsidiary, Applied DNA Clinical Labs, LLC, dedicated to the commercial development of its tests in virology, for the detection of COVID-19, and in oncology, for the detection and enumeration of invasive circulating tumor cells.The company also said the amendment of its EUA for its molecular test for SARS-CoV-2 was approved by FDA to include extraction and concentration of the viral RNA by a magnetic method of nucleic acid extraction that lends itself easily to high throughput scaling with robotics and diversifies the two extraction methods already covered by the existing EUA.The stock was advancing 16.21% to $9.32 premarket Thursday.Acer Announces Positive Data For Taste-Masked Immediate Release Formulation Of Urea Cycle Disorder Drug Acer Therapeutics Inc (NASDAQ: ACER) announced data from a food effect study in healthy volunteers showing that administration of ACER-001, its taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with urea cycle disorders compared to treatments requiring administration with food.The company said it expects to submit the ACER-001 NDA in the first half of 2021, assuming successful completion of additional nonclinical work and long-term stability data, and subject to additional capital.The stock was up 19.88% at $3.86 premarket Thursday.FDA Accepts AstraZeneca's Application For Brilinta Label Expansion With Priority Review AstraZeneca plc (NYSE: AZN) said the FDA has accepted a supplemental New Drug Application and granted Priority Review for Brilinta for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.The stock was adding 0.3% to $54.35 premarket Thursday.Osmotica Announces FDA Approval For Drug To Treat Droopy Eyelid Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) said the FDA has approved Upneeq, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid that can limit field of vision.In premarket trading Thursday, the stock was jumping 5.35% to $6.70.Shockwave Medical Gets Mixed Ruling In Patent Appeal Case The Patent Trial and Appeal Board ruled that a key claim is valid in the inter partes review initiated against Shockwave Medical Inc (NASDAQ: SWAV) by Cardiovascular Systems Inc (NASDAQ: CSII). "We are very pleased that the court validated claim 5 of our '371 patent, which protects the broad embodiment of our IVL technologies," said Doug Godshall, CEO of Shockwave.The PTAB ruled that some claims of a second patent are valid and that all claims of a third patent are invalid.Shockwave shares were down 0.81% at $46.60 premarket Thursday.Altimmune Teams With DynPort On COVID-19 Vaccine Funding Altimmune said it has entered into a teaming agreement with DynPort Vaccine Company, a General Dynamics Information Technology company, to coordinate U.S. government funding efforts and, if successful, to provide program management, drug development activity integration and regulatory support for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate.Offerings Otonomy Inc (NASDAQ: OTIC) said it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by the company. In lieu of common stock, the company plans to offer to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.The stock was sliding 5.34% to $3.37 premarket.Revolution Medicines Inc (NASDAQ: RVMD) priced its underwritten public offering of 6 million shares of common stock at $26 per share, for raising gross proceeds of $156 million. All of the shares are being offered by the company. The company expects the offering to close July 13.The stock was seen receding 1.85% to $27.50 premarket Thursday.NanoViricides Inc (NYSE: NNVC) announced the commencement of an underwritten public offering. The company said it intends to use the net proceeds from the offering to fund general corporate purposes, including its drug development programs for COVID-19 and for shingles.The stock fell 8.04% to $8.01 premarket Thursday.Qualigen Therapeutics Inc (NASDAQ: QLGN) said it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $8 million in stock: 1.2 million common shares, 780,198 pre-funded warrants and 1.98 million common warrants at a combined purchase price of $4.165 in a registered direct offering priced at-the-market.Qualigen shares were trading 1.95% higher to $4.19 premarket Thursday.Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Novavax Lands .6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold * Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/09/2020
|
Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the formation of a wholly-owned subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), dedicated to the commercial development of its tests in Virology, for the detection of COVID-19, and in Oncology, for the detection and enumeration of invasive Circulating Tumor Cells (iCTCs). With the formation of ADCL, the Company is executing on a strategy to expand its market reach through value-added services complementary to a growing portfolio of diagnostic assays attractive to a broader number of qualified labs. ADCL allows Applied DNA to be a direct beneficiary of its own diagnostics development beyond the sales of kits to qualified laboratories, and provides the clinical sampling framework necessary to obtain the data required by State and Federal regulatory authorities to develop and improve diagnostics and vaccines in the face of a pandemic with rapidly shifting genetics and infectious behavior.
- 07/09/2020
|
Anti-Counterfeit Packaging Market Analysis Highlights Impact of COVID-19 2020-2024 | Booming E-commerce Industry to Boost the Market Growth | Technavio
- The Global Anti-Counterfeit Packaging Market will grow by $ 105.86 bn during 2020-2024
- 07/07/2020
|
Applied DNA Analyst Says Coronavirus Testing, Vaccine Work Could Drive Major Upside
- Shares of Applied DNA Sciences Inc (NASDAQ: APDN), which is in the race to develop a vaccine for the novel coronavirus, offer an attractive buying opportunity, according to H.C. Wainwright.The Applied DNA Analyst: Yi Chen initiated coverage of Applied DNA shares with a Buy rating and $18 price target, suggesting roughly 132% upside from current levels. The Applied DNA Thesis: Applied DNA's LinearDNA large-scale polymerase chain reaction-based manufacturing platform offers many benefits over the limitations of a large-scale plasmid-based circular DNA approach, especially in the areas of speed, scale, safety and customization, Chen said in a Thursday initiation note. (See his track record here.)The company has been producing large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets, the analyst said. Applied DNA's real-time reverse transcription PCR test for qualitative detection of the SARS-CoV-2 -- which has been validated and has FDA Emergency Use Authorization -- can be used on high-throughput PCR systems for population screening, he said.The company is on track to ship the assay kits to labs across the U.S. during this quarter, Chen said. Applied DNA is developing a linear DNA-based COVID-19 vaccine in collaboration with the Italian biotech firm Takis Biotech, the analyst said.The data from the linear DNA version in animal studies of the vaccine is due shortly."Given the company's rapid responses and the substantial markets of COVID-19 testing and vaccines, we rate shares at Buy with a 12-month price target of $18," Chen said. APDN Price Action: At last check, Applied DNA shares were adding 7.87% to $8.36.Related Links:The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates Latest Ratings for APDN DateFirmActionFromTo Jul 2020HC Wainwright & Co.Initiates Coverage OnBuy Nov 2019Maxim GroupUpgradesHoldBuy Aug 2018Maxim GroupMaintainsBuyBuy View More Analyst Ratings for APDN View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO * The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger * The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/02/2020
|
H.C. Wainwright Initiates a Buy Rating on Applied DNA Sciences (APDN) - Markets
- In a report released today, Yi Chen from H.C. Wainwright initiated coverage with a Buy rating on Applied DNA Sciences
- 07/02/2020
|
Applied DNA Analyst Says Coronavirus Testing, Vaccine Work Could Drive Major Upside
- Shares of Applied DNA Sciences Inc (NASDAQ: APDN), which is in the race to develop a vaccine for the novel coronavirus, offer an attractive buying opportunity, according to...
- 07/02/2020
|
Applied DNA Sciences Set to Join Russell Microcap Index
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, is set to join the Russell Microcap® Index (the "Index") at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the U.S. market opens on June 29, according to a preliminary list of additions posted on June 19 to the Russell Reconstitution website.
- 06/26/2020
|
Applied DNA Sciences Set to Join Russell Microcap Index
- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that ena
- 06/26/2020
|
LuLu celebrates ‘king of fruits’ in annual mango festival
- LuLu Hypermarket is hosting its annual mango festival, “Mango World,” with 50 varieties of the fruit from different countries on show. The hypermarket has sourced mangoes from 10 tropical countries for the event that is being held across all its branches in Saudi Arabia. A number of mango-based desserts, deli treats, and other processed and packaged mango products are also on offer. The annual summer festival that celebrates the “king of fruits” will run until June 23 at all LuLu hypermarkets across the country.
- 06/22/2020
|
Signify’s UV-C radiation can inactivate coronavirus: Research
- Signify, a global brand in professional and consumer lighting, and the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University in the US have conducted research that validates the effectiveness of Signify’s UV-C light sources on the inactivation of SARS-CoV-2, the virus that causes COVID-19.
- 06/22/2020
|
William W. Montgomery Buys 40,000 Shares of Applied DNA Sciences Inc (NASDAQ:APDN) Stock
- Applied DNA Sciences Inc (NASDAQ:APDN) insider William W. Montgomery bought 40,000 shares of Applied DNA Sciences stock in a transaction that occurred on Thursday, June 18th. The shares were bought at an average cost of $5.25 per share, with a total value of $210,000.00. Following the acquisition, the insider now directly owns 215,000 shares in […]
- 06/20/2020
|
Lighting firm Signify says UV light breaks down coronavirus particles in seconds
- Dutch firm Signify teamed up with Boston University researchers to establish how effective UV light is at degrading coronavirus.
- 06/17/2020
|
Researchers find indoor UV light degrades coronavirus
- Signify, the world’s largest lighting manufacturer, said on Tuesday researchers at Boston University had confirmed an ultraviolet light made by the company works to degrade most coronavirus in a la…
- 06/16/2020
|
Lighting maker Signify: UV light 'degrades' coronavirus quickly
- Signify, the world's largest lighting manufacturer, said on Tuesday researchers at Boston University had confirmed an ultraviolet light made by the company works to degrade most coronavirus in a laboratory setting in a matter of seconds.
- 06/16/2020
|
Lighting maker Signify: UV light 'degrades' coronavirus quickly
- Signify, the world's largest lighting manufacturer, said on Tuesday researchers at Boston University had confirmed an ultraviolet light made by the company works to degrade most coronavirus in a laboratory setting in a matter of seconds.
- 06/16/2020
|
Lighting maker Signify: UV light 'degrades' coronavirus quickly
- Lighting maker Signify: UV light 'degrades' coronavirus quickly
- 06/16/2020
|
Edited Transcript of APDN earnings conference call or presentation 14-May-20 8:30pm GMT
- Q2 2020 Applied DNA Sciences Inc Earnings Call
- 06/13/2020
|
Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company," "our") announced today it secured a $40,000 economic development grant from National Grid to support the Company’s efforts associated with the manufacture of COVID-19-related therapeutics and diagnostics programs. National Grid is one of the largest investor-owned energy companies in the U.S. and serves more than 20 million customers throughout New York, Massachusetts, and Rhode Island.
- 06/09/2020
|
Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates
- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company,” “our”) announced today it secured a $40,000 economic development grant from
- 06/09/2020
|
Applied DNA Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today provided an update related to the development of linear-DNA form of COVID-19 vaccine candidates with development partner Takis Biotech ("Takis"). Subsequent to the Company’s announcement on May 4, 2020 that first injections of plasmid-based DNA vaccine candidates developed by Takis produced neutralizing antibodies in test animals, linear DNA versions of the vaccine candidates manufactured by Applied DNA began dose-response trials the results of which the Company expects to publish in June 2020.
- 06/08/2020
|
Anti-Counterfeit Packaging Technologies Market Status and Business Outlook 2020 to 2026 | Du Pont, UPM, Illinois Tool Works, Zebra Technologies Corp,3M, Avery Dennison
- Global Anti-Counterfeit Packaging Technologies Market Size, Status And Forecast 2020 Jun 03, 2020 (Market Insight Reports) --
The report provides a unique...
- 06/03/2020
|
Medmira: From Functional Bankruptcy To Canada's Biggest COVID-19 Hype Stock (OTCMKTS:MMIRF)
- Medmira has gone on an incredible run and is Canada's biggest COVID-19 hype play as the company develops its COVID-19 antibody test kit. Medmira has a $15 milli
- 06/01/2020
|
Applied DNA to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27
- Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced that Dr. James Hayward, president & CEO, will participate on a panel titled ‘COVID-19 Testing and Monitoring’ at 12:15 p.m. ET on Wednesday, May 27, 2020 as part of Maxim Group’s COVID-19 Virtual Conference Series. The panel will be moderated by Jason McCarthy, Ph.D., Maxim Group Senior Managing Director, Biotechnology.
- 05/21/2020
|
Applied DNA to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27
- Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that en
- 05/21/2020
|
News Flash: One Applied DNA Sciences, Inc. (NASDAQ:APDN) Analyst Has Been Trimming Their Revenue Forecasts
- The latest analyst coverage could presage a bad day for Applied DNA Sciences, Inc. (NASDAQ:APDN), with the covering...
- 05/19/2020
|
Analysts Have Lowered Expectations For Applied DNA Sciences, Inc. (NASDAQ:APDN) After Its Latest Results
- As you might know, Applied DNA Sciences, Inc. (NASDAQ:APDN) last week released its latest second-quarter, and things...
- 05/16/2020
|
Applied DNA Sciences Tackles COVID-19 on Three Fronts; Analyst Says ‘Buy’
- Applied DNA Sciences (APDN) is a tiny microcap healthcare stock with a 37-year history in business -- but no profits, and almost no (less than $5 million annual) revenues. Despite this somewhat mixed resume to recommend it, Applied DNA Sciences stock shot through the roof on Thursday, spiking 71% on news that the FDA has approved its new coronavirus detection test for emergency use.The test in question, a "patent-pending Linea COVID-19 RT-PCR test for COVID-19," is a "reverse transcription, Real Time Polymerase Chain Reaction" test to detect the presence of the SARS-CoV-2's "Spike (S) gene" in a person's bloodstream. It is designed to run on the FDA-approved Applied Biosystems QuantStudio Dx real-time PCR detection machine, "which allows for testing results for up to 94 samples within one hour, or more than 2,000 tests in 24 hours per device," explains Applied DNA Sciences.The Emergency Use Authorization (EUA) under which the test can be used is not equivalent to an actual FDA "approval" of the test. It does, however, permit the test to be used in the hope it will prove effective in diagnosing a "disease or condition" -- in this case the novel coronavirus SARS-CoV-2 -- during a public health emergency such as the present COVID-19 pandemic.Nor is this the only iron that Applied DNA Sciences has in the coronavirus fire.As Maxim analyst Anthony Vendetti explained, Applied DNA Sciences is also one of several biotech firms working on a vaccine to prevent infection with COVID-19. Specifically, on May 4, the company claimed success in generating antibodies to fight the SARS-CoV-19 coronavirus in response to a vaccine administered to mice in a preclinical trial.Applied DNA Sciences' vaccine focuses on the same spike gene that its test aims to detect, "a surface protein that plays a key role in viral entry into host cells," explains Vendetti. The analyst seems especially impressed with the fact that Applied DNA Sciences' vaccine, in contrast to others being worked on elsewhere, "is effective without insertion into the patient's genome" and "can be rapidly revised to accommodate mutational drift (in the virus)." This could indeed become important if the novel coronavirus mutates into even more novel forms over time.Additionally, Vendetti reminds investors that in April, Applied DNA Sciences was admitted to the FDA's "Emerging Technology Program (ETP) for the molecular tagging of Solid Oral Dosage Forms [which] serves to help promote the adoption of innovative approaches to pharmaceutical product design and manufacturing."Of these three coronavirus-related efforts on Applied DNA Sciences' part, Vendetti seems to place the most weight on the vaccine, albeit (a) it's not been admitted to any clinical trials yet and (b) the COVID-19 test news hadn't come out yet at the time the analyst made his recommendation to buy Applied DNA Sciences stock.Citing "outyear revenue estimates" (presumably 2022 and beyond) and best guesses at Applied DNA Sciences' "share of the COVID-19 vaccine market and share of revenue generated per vaccine," Vendetti thinks Applied DNA Sciences stock could be worth as much as $18 a share a year from now, and assigns the stock a "buy" rating.To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 05/15/2020
|
Those Who Purchased Applied DNA Sciences (NASDAQ:APDN) Shares Five Years Ago Have A 85% Loss To Show For It
- It is a pleasure to report that the Applied DNA Sciences, Inc. (NASDAQ:APDN) is up 337% in the last quarter. But will...
- 05/15/2020
|
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2020 Results - Earnings Call Transcript
- Applied DNA Sciences, Inc. (NASDAQ:APDN) Q2 2020 Earnings Conference Call May 14, 2020 04:30 PM ET Company Participants Judy Murrah - Chief Information Officer
- 05/15/2020
|
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 14)
Allogene Therapeutics Inc (...
- 05/15/2020
|
Applied DNA Reports 2020 Fiscal Second Quarter Financial Results
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced consolidated financial results for the fiscal second quarter and the six months ended March 31, 2020.
- 05/14/2020
|
Stocks trade slightly lower as 36 million jobs vanish in wake of coronavirus, Trump turns hawkish on China
- U.S. stocks traded down Thursday, but off earlier lows after data showed nearly another 3 million Americans lost jobs last week, down slightly from the prior...
- 05/14/2020
|
Stocks slump at the open as 36 million jobs vanish in wake of coronavirus, Trump turns hawkish on China
- U.S. stock-index futures traded sharply lower Thursday after data showed nearly another 3 million Americans lost jobs last week, down slightly from the prior...
- 05/14/2020
|
Applied DNA's Coronavirus Test Cleared by FDA for Emergency Use
- Applied DNA Sciences' coronavirus test kit is now cleared under the FDA's emergency-use authorization.
- 05/14/2020
|
The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs May 13.) * AstraZeneca plc (NYSE: AZN) * AtriCure Inc. (NASDAQ: ATRC) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Catalent Inc (NYSE: CTLT) (announced a collaboration with Ennaid Therapeutics to develop an oral antiviral treatment targeted at COVID-19) * Co-Diagnostics Inc (NASDAQ: CODX) (reacted to disappointing sensitivity data reported by Abbott Laboratories (NYSE: ABT) for its rapid molecular testing for SARS-CoV-2) * CytomX Therapeutics Inc (NASDAQ: CTMX) * Forward Pharma A/S (NASDAQ: FWP) (announced extended timing for patent appeal) * Immunovant Inc (NASDAQ: IMVT) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * Minerva Neurosciences Inc (NASDAQ: NERV) * Orgenesis Inc (NASDAQ: ORGS) (announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * Translate Bio Inc (NASDAQ: TBIO) * Zai Lab Ltd (NASDAQ: ZLAB) (announced Chinese regulatory nod for its Optune in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma and Optune monotherapy for recurrent glioblastoma) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech stocks that hit 52-week lows May 13.) * Genfit SA (NASDAQ: GNFT) * Recro Pharma Inc (NASDAQ: REPH) * Sensus Healthcare Inc (NASDAQ: SRTS) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN)Stocks In Focus ASCO Abstracts A slew of biotechs reacted to publication of online abstracts that are set to be presented at the 2020 American Society of Clinical Oncology Annual Virtual Meeting May 29-31.Updated safety and initial efficacy data for Arvinas Inc's (NASDAQ: ARVN) Phase 1/2 clinical trial of ARV-110 in men with metastatic castration-resistant prostate cancer showed two patients with ongoing confirmed prostate-specific antigen responses, including one with an unconfirmed partial tumor response.The stock was down 17.65% at $42 in Thursday's premarket session. Allogene Therapeutics Inc's (NASDAQ: ALLO) abstract consisted of first data from its Phase 1 dose escalation ALPHA study of CAR-T cell therapy ALLO-501 in relapsed/refractory non-Hodgkin lymphoma.Preliminary data on the first nine patients treated with escalating doses of ALLO-501 and a lower dose of ALLO-647 showed no dose limiting toxicities or graft-vs-host disease and a 78% overall response rate, with three complete responses and four partial responses.The stock was up 22.01% at $37.80 in the premarket session. ImmunoGen, Inc.'s (NASDAQ: IMGN) abstract consisted of initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin in patients with medium and high folate receptor alpha-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate.The company said the combination showed promising anti-tumor activity and favorable tolerability, with a confirmed overall response rate of more than 60%.The stock was trading 5.39% higher at $4.30 in the premarket session. MEI Pharma Inc (NASDAQ: MEIP) announced updated data from a Phase 1b study of ME-401 in clinical development for the treatment of B-cell malignancies that showed treatment was generally well-tolerated, with an 83% overall response rate in patients with relapsed or refractory follicular lymphoma.MEI shares were up 2.47% at $2.90 premarket Thursday.MacroGenics Inc (NASDAQ: MGNX) announced preliminary results from two of its studies.The Phase 1 dose escalation and expansion clinical trial of MGD013 -- in combination with margetuximab, its investigational Fc-engineered monoclonal antibody targeting HER-2 -- suggested a response in approximately 40% of late-stage HER-2-positive tumors that compares favorably to low response rates for HER-2-directed agents and checkpoint blockades.Separately, the company announced early results from an ongoing Phase 1 study of MGC018, an ADC directed against B7-H3, showing preliminary signals of anti-tumor effects, including prostate-specific antigen reductions of 50% or more in five of seven patients with late-stage prostate cancer.The stock slumped 19.81% to $21.25 in after-hours trading.See also: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight CytomX announced further details of oral and poster presentations to be made at the month end's ASCO meeting.The stock was down 19.7% at $21.28 at the time of publication. Genocea Biosciences Inc (NASDAQ: GNCA) announced updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the company's lead neo-antigen vaccine candidate, which showed that seven of the eight patients enrolled have continued without progression with a median follow-up of over one year.View more earnings on IBBThe stock was up 7.92% at $2.86 at the time of publication. Verona Pharma Receives Positive End-Of-Phase 2 Feedback From FDA VERONA PHARMA P/S' ADR (NASDAQ: VRNA) released details of the FDA's written response following the end-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease. The company said the response supported the continuation of its planned Phase 3 study. Verona expects to start the study in 2020.Verona shares were up 22.28% at $4.61 at the time of publication. Sanofi's Hemolysis Drug Accepted For Priority Review Sanofi SA (NASDAQ: SNY) said the FDA granted priority review of its BLA for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease, or CAD. Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s. The PDUFA date has been set for Nov. 13.AIM ImmunoTech Gets FDA Nod For Starting Human Study of Combo Treatment In Cancer Patients With COVID-19 AIM ImmunoTech Inc (NYSE: AIM) said the FDA authorized the first human trial assessing the safety and effectiveness of its lead asset, Ampligen, in combination with interferon alfa-2b, in cancer patients with COVID-19.The stock was rallying by 36.17% to $3.20 in the premarket session. Illumima Marketing Chief To Depart Illumina, Inc.'s (NASDAQ: ILMN) global marketing head Omead Ostadan is leaving the company after more than a decade and is becoming president and COO of Seer Inc. effective June 29. Illumina shares were down 17.74% at $266.03 in the premarket session. Lilly, Innovent's Cancer Drug Aces Midphase Chinese Study In Esophageal Cancer Hong Kong biotech Innovent Biologics announced along with Eli Lilly And Co (NYSE: LLY) that the Phase 2 study of Tyvyt in China, dubbed ORIENT-2, met its primary endpoint of overall survival. The study evaluated Tyvyt monotherapy compared to chemotherapy as a second-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma.Biopharmx Shareholders Approve Reverse Merger With Timber Pharma Biopharmx Corp (NYSE: BPMX) announced that all proposals related to its proposed merger with Timber Pharmaceuticals were approved by stockholders at a special meeting held May 13. The company said it expects the deal to close on or about May 18,, contingent upon customary closing conditions and regulatory approvals.Upon closing of the transaction, the combined company will change its name to "Timber Pharmaceuticals, Inc." Its shares are expected to commence trading on the NYSE American market under the ticker symbol "TMBR."The stock was roaring higher by 40.46% to 66 cents in premarket trading Thursday. Applied DNA's COVID-19 Diagnostic Assay Kit Receives Emergency Use Authorization Applied DNA Sciences Inc (NASDAQ: APDN) said the FDA has issued Emergency Use Authorization, or EUA, for its Linea COVID-19 RT-PCR test to be performed in clinical labs in the U.S. certified under Clinical Laboratory Improvement Amendments to perform high complexity tests.Applied DNA shares were ripping 79.98% higher to $16 at the time of publication. Xeris Signs Distribution Deal Outside US For Low Blood Pressure Drug Xeris Pharmaceuticals Inc (NASDAQ: XERS) said it has signed an exclusive agreement with AIM-listed Clinigen Group to distribute its low blood pressure drug Gvoke outside of the U.S., where it is not currently licensed.Gvoke has not yet been approved in Europe.Immunic Gets Regulatory Nod For Phase 2 Study Of Coronavirus Drug Immunic Inc (NASDAQ: IMUX) said it has received the first regulatory approval from Germany's BfArM to initiate a Phase 2 study of its selective oral DHODH inhibitor, IMU-838, in COVID-19.The study is designed as a multicenter, randomized, placebo-controlled and double-blinded study, and it intends to study 230 patients with moderate COVID-19.The company said it expects to dose the first patient later this month and make top-line data from the study available later this year.In premarket trading Thursday, the stock was surging 19.84% to $12.20. Earnings RA Medical Systems Inc (NYSE: RMED) reported first-quarter revenue of $1.4 million, down from $1.7 million a year ago and lower than the $1.58-million consensus estimate.The loss widened from $1.16 per share to 56 cents per share, while analysts estimated a loss of 34 cents per share.The stock was declining 5.97% to 90 cents at the time of publication. Biocept Inc's (NASDAQ: BIOC) first-quarter revenue rose 41% year-over-year to $1.4 million. The loss per share narrowed from 61 cents to 11 cents.The stock was trading 4.83% higher to 46 cents in Thursday's premarket session. Offerings Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) priced its 2.4-million-share common stock offering at $18.25 per share. The company expects to raise gross proceeds of $75 million from the offering.
- 05/14/2020
|
Shares of Applied DNA Sciences jump 66% on regulatory authorization of its COVID-19 test
- Shares of Applied DNA Sciences Inc. [: apdn] soared 66.2% in premarket trading on Thursday after the company announced emergency use authorization from the...
- 05/14/2020
|
Shares of Applied DNA Sciences jump 66% on regulatory authorization of its COVID-19 test
- Shares of Applied DNA Sciences Inc. [: apdn] soared 66.2% in premarket trading on Thursday after the company announced emergency use authorization from the Food and Drug Administration for its COVID-19 test. The machine that runs Applied's test can process 94 samples per hour and more than 2,000 tests per day, the company said. The FDA has issued emergency use authorizations to about 50 molecular tests that can detect COVID-19. Applied's stock is up 112.1% year-to-date, while the S&P; 500 is down 12.7%.
- 05/14/2020
|
Applied DNA Receives FDA Emergency Use Authorization for COVID-19 Diagnostic Assay Kit
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company," "our") announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the clinical use of the Company’s patent-pending Linea™ COVID-19 RT-PCR test for COVID-19. Clinical laboratories in the United States certified under Clinical Laboratory Improvement Amendments (CLIA) to perform hi complexity tests. CLIA labs can immediately begin ordering and using the Linea™ COVID-19 assay kit to detect SARS-CoV-2, the virus that causes COVID-19.
- 05/14/2020
|
Applied DNA Receives FDA Emergency Use Authorization for COVID-19 Diagnostic Assay Kit
- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company,” “our”) announced today that the U.S. Food and Drug Administration (FDA) has
- 05/14/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Applied DNA Schedules Fiscal 2020 Second Quarter Financial Results Conference Call for Thursday, May 14, 2020 at 4:30 PM ET
- Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2020 second quarter ended March 31, 2020 after market close on Thursday, May 14, 2020. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet.
- 05/07/2020
|
Stock Charts To Watch: CARS, DQ, LPSN, OSTK, SE, SPCE
- Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Natural Gas Futures, Dynavax Technologies Corporation, Horizon Pharma PLC. Read Harry Boxer's latest article on Investing.com
- 05/07/2020
|
Applied DNA Receives Approximately $5.3 Million in Net Proceeds from Warrant Exercise
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, has received approximately $5.3 million in net proceeds calendar year to date as a result of the exercise of equity warrants.
- 05/06/2020
|
Applied DNA Applies to U.S. FDA for Emergency Use Authorization for COVID-19 Diagnostic Kit
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company," "our") today announced that it applied prior to the end of April for U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its Linea™ COVID-19 diagnostic candidate to detect SARS-CoV-2, the novel coronavirus that causes the disease COVID-19. Validation for the EUA was completed in collaboration with Stony Brook University Hospital; the company’s neighbor and collaborator on campus.
- 05/05/2020
|
Important Technical Indicators to watch- Applied DNA Sciences, Inc. (NASDAQ:APDN)’s E-P-S strolling at -7.33, - Stocks Equity
- On Monday, Applied DNA Sciences, Inc. (NASDAQ:APDN)’s highest estimates of price target are $8.00 and low forecast is $8.00 based on the opinion of 1 [...]
- 05/04/2020
|
Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company" or "we/our") today announced with its COVID-19 vaccine development partner Takis Biotech ("Takis") that the first injections of the DNA vaccine candidates against the Spike protein (product of the S gene) of the SARS-CoV-2 virus, cause of the COVID-19 disease, have produced neutralizing antibodies in test animals. The studies were completed at the renowned Lazzaro Spallanzani ("Spallanzani") National Institute for Infectious Diseases in Rome. These initial results were obtained using plasmids (the templates for LinearDNA™) to baseline results; Applied DNA’s linear DNA dose-response trials begin this week.
- 05/04/2020
|
Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals
- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company” or “we/our”) today announced with its COVID-19 vaccine development partner Ta
- 05/04/2020
|
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 05/02/2020
|
Applied DNA Accepted Into U.S. FDA’s Emerging Technology Program, Creating Pathway for Molecular Tagging of Pharmaceuticals and Packaging
- STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) today announced that the Emerging Technology Team (ETT) of the U.S. Food and Drug Administration (FDA) has accepted the Company into its Emerging Technology Program (ETP) for the molecular tagging of Solid Oral Dosage Forms (SODF). The ETP serves to help promote the adoption of innovative approaches to pharmaceutical product design and manufacturing and offers technology companies and their pharmaceutical customers the opportunity to discuss, identify, and resolve potential technical and regulatory pathways early in the development and implementation of novel technology.
- 04/30/2020
|
Inovio completes enrollment in COVID-19 vaccine study; shares up 5% premarket
- Inovio Pharmaceuticals (NASDAQ:INO) announces the full enrollment of 40 healthy volunteers in a Phase 1 clinical trial of INO-4800, its COVID-19 DNA vaccine candidate.All participants have received th
- 04/28/2020
|
Insights on the Worldwide Anti-Counterfeit Packaging Industry to 2024 - Drivers, Challenges and Trends
- Dublin, April 24, 2020 -- The "Global Anti-Counterfeit Packaging Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The.
- 04/24/2020
|
BYND, OPK among premarket gainers
- Energous (NASDAQ:WATT) +143% on FCC certification.Vaxart (NASDAQ:VXRT) +32% on encouraging COVID-19 vaccine data.My Size (NASDAQ:MYSZ) +27%.Applied DNA Sciences (NASDAQ:APDN) +21% on deal for COVID-19
- 04/21/2020
|
The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) * Abbott Laboratories (NYSE: ABT) * Acceleron Pharma Inc (NASDAQ: XLRN) * Arvinas Inc (NASDAQ: ARVN) * Chembio Diagnostics Inc (NASDAQ: CEMI) *
- 04/21/2020
|
Applied DNA High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") today announced the signing of an Agreement with Stony Brook University Hospital (the "Hospital") to validate and implement the Company’s patent-pending nucleic acid diagnostic (LineaCOVID-19™) to detect and quantify in diagnostic samples the presence of SARS-CoV-2, the virus that causes the disease, COVID-19. Validation is expected to begin immediately with results to be used to support the Company’s application to the U.S. Food and Drug Administration (FDA) before the end of April 2020 for Emergency Use Authorization (EUA).
- 04/21/2020
|
Applied DNA Sciences (NASDAQ:APDN) Given "Buy" Rating at Maxim Group
- Applied DNA Sciences (NASDAQ:APDN)‘s stock had its “buy” rating reaffirmed by Maxim Group in a research report issued to clients and investors on Friday, TipRanks reports. They presently have a $8.00 target price on the technology company’s stock. Maxim Group’s target price points to a potential upside of 45.45% from the stock’s previous close. Separately, […]
- 04/18/2020
|
GT, RAD among premarket losers
- Diamond Offshore Drilling (NYSE:DO) -35% after skipping interest payment.Athersys (NASDAQ:ATHX) -26% after pricing equity offering.InVivo Therapeutics Holdings (NASDAQ:NVIV) -18% after launch of $3M d
- 04/16/2020
|
Mid-Afternoon Market Update: Dow Falls 1.5%; Pfenex Shares Plummet
- Toward the end of trading Wednesday, the Dow traded down 1.5% to 23589.88 while the NASDAQ fell 0.98% to 8,432.13. The S&P also fell, dropping 1.78% to 2,795.28.
The U.S. is...
- 04/15/2020
|
Mid-Day Market Update: Crude Oil Down 3%; Applied DNA Sciences Shares Jump
- Midway through trading Wednesday, the Dow traded down 2.63% to 23319.37 while the NASDAQ fell 1.99% to 8346.64. The S&P also fell, dropping 2.73% to 2,768.24.
The U.S. is the...
- 04/15/2020
|
Mid-Morning Market Update: Markets Open Lower; Bank of America Profit Misses Views
- Following the market opening Wednesday, the Dow traded down 2.89% to 23,258.44 while the NASDAQ fell 2.11% to 8,336.48. The S&P also fell, dropping 2.80% to 2,766.36.
The U.S...
- 04/15/2020
|
U.S. STOCKS ON THE MOVE-Banks, Aphria, Tesla, UnitedHealth, J.C. Penney
- * Eikon search string for individual stock moves:* The Day Ahead newsletter: The Morning News Call newsletter: Wall Street’s main indexes were set to slide at the open on Wednesday, as a reco…
- 04/15/2020
|
APHA, AAL among premarket gainers
- Applied DNA Sciences (NASDAQ:APDN) +61% on advancement of COVID-19 vaccine candidates.Comstock Holding Companies (NASDAQ:CHCI) +45% on FY results.BOQI International Medical (NASDAQ:BIMI) +25% on formi
- 04/15/2020
|
The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Acceleron Pharma Inc (NASDAQ: XLRN) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Kala Pharmaceuticals
- 04/15/2020
|
18 Industrials Stocks Moving In Wednesday's Pre-Market Session
- Gainers
• Applied DNA Sciences, Inc. (NASDAQ:APDN) stock moved upwards by 45.05% to $6.60.
• JetBlue Airways, Inc. (NASDAQ:JBLU) shares rose 12.66% to $10.41. The most...
- 04/15/2020
|
30 Stocks Moving in Wednesday's Pre-Market Session
- Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares rose 59.3% to $7.25 in pre-market trading. Applied DNA has shipped coronavirus LinearDNA vaccine candidates to Italian...
- 04/15/2020
|
U.S. STOCKS ON THE MOVE-Goldman Sachs, Johnson & Johnson, Tesla, Aphria
- * Eikon search string for individual stock moves:* The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures retreated on Wednesday for a second time this week, as a slid…
- 04/15/2020
|
Applied DNA Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it has completed design qualification, production and shipment of five COVID-19 vaccine candidates to Italy-based Takis Biotech ("Takis"), a developer of cancer vaccines and the Company’s COVID-19 vaccine development partner, to support preclinical animal testing that will begin immediately. The vaccine candidates were produced by the Company’s proprietary PCR-based LinearDNA™ manufacturing systems.
- 04/15/2020
|
Applied DNA to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5
- Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020. Applied DNA CEO Dr. James Hayward will join a panel of drug developers to share his insights on how gene-based vaccines, such as those being advanced by the Company and its joint development partner, Rome, Italy-based Takis Biotech, are at the forefront of COVID-19 vaccine development programs. The panel, entitled ‘COVID-19 (Vaccine, Treatment, Testing)’, is scheduled for 2:00 p.m. ET to 3:30 p.m. ET. To RSVP for the virtual conference, please click through: Maxim Group’s Infectious Disease Virtual Conference.
- 04/14/2020
|
RDS.A, ARNC among top premarket gainers
- ION Geophysical (NYSE:IO) +120% on expecting big jump in Q1 revenues.Neptune Wellness Solutions (NASDAQ:NEPT) +47% on receiving health Canada authorization to commercialize natural, plant-based hand s
- 04/02/2020
|
Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, and Takis Biotech ("Takis"), a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate. Production of all vaccine candidates is expected to be completed this month at Applied DNA’s LinearDNA™ production facility in Stony Brook, N.Y. All vaccine candidates have also been approved by Italy’s Ministry of Health for preclinical animal testing that is scheduled to begin in late April 2020.
- 04/02/2020
|
Anti-Counterfeit Packaging for Healthcare Market 2020 Global Industry Analysis, Size, Share, Growth, Trends, Key Players and Forecast to 2026
- Apr 01, 2020 (The Expresswire) --
"Final Report will add the analysis of the impact of COVID-19 on this industry." “Anti-Counterfeit Packaging for Healthcare...
- 04/01/2020
|
Is Applied DNA Sciences, Inc. (NASDAQ:APDN) Excessively Paying Its CEO?
- In 2006 James Hayward was appointed CEO of Applied DNA Sciences, Inc. (NASDAQ:APDN). First, this article will compare...
- 03/31/2020
|
Applied DNA Ships LinearDNA™ to Another Development Customer
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced today that it has shipped two CAR T amplicons proprietary to the biologics subsidiary of a U.S.-based, global biopharmaceutical company. The customer is one of nearly two dozen development customers in various stages of evaluating the use of linear DNA manufactured by the Company.
- 03/26/2020
|
The Coronavirus Effect: Pandemic Stocks and Sympathy Plays
- Right now, that means you need to keep up with pandemic stocks and sympathy plays. How can you find opportunities? Read on!
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) (follow-on rally from Friday's news of FDA authorization
- 03/24/2020
|
Applied DNA Files Provisional Patent Application for High Sensitivity COVID-19 Diagnostic Assay with U.S. Patent and Trademark Office
- Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and diagnostics, announced today the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for its diagnostic assay under development for SARS-CoV-2, the virus that causes the disease COVID-19. The application follows the Company’s announcement on March 19, 2020 that it had completed the design of its COVID-19 detection assay.
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Applied DNA Sciences (APDN) Receives a Buy from Maxim Group
- Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Applied DNA Sciences (APDN) today and set a price target of $8.00. The company's shares
- 03/20/2020
|
Applied DNA Sciences (APDN) Receives a Buy from Maxim Group
- Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Applied DNA Sciences (APDN – Research Report) today and set
- 03/20/2020
|
Profit-taking pressures Moderna after Hahn comments on vaccine timeline
- Moderna (MRNA -15.9%) slumps on more than double normal volume on the heels of comments today from FDA Commissioner Stephen Hahn (during the Coronavirus Task Force briefing) that approval of a COVID-1
- 03/19/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Hot Topics Recap: Coronavirus
- Recap of stories on Business Wire related to Coronavirus
- 03/11/2020
|
Hot Topics Recap: Coronavirus
- Recap of stories on Business Wire related to Coronavirus.
- 03/06/2020
|
Hot Topics Recap: Coronavirus
- Recap of stories on Business Wire related to Coronavirus
- 03/04/2020
|
Healthcare dominates premarket losers amidst coronavirus situation
- Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NASDAQ
- 03/03/2020
|
TSLA, TWTR among premarket gainers
- Daxor (NYSEMKT:DXR) +77% on coronavirus news.Forty Seven (NASDAQ:FTSV) +62% as Gilead Sciences makes $95.50 per share cash offer.Trillium Therapeutics (NASDAQ:TRIL) +51% as Gilead Sciences makes $95.5
- 03/02/2020
|
Applied DNA, Takis Biotech Partner To Design COVID-19 Vaccines For Animal Testing
- Applied DNA Sciences Inc (NASDAQ: APDN) shares gapped higher Monday after the DNA manufacturing company announced an update to its COVID-19 vaccine development partnership....
- 03/02/2020
|
Hot Topics Recap: Coronavirus
- Recap of Coronavirus stories on Business Wire
- 02/28/2020
|
NVAX, INO among premarket gainers
- Allied Healthcare Products (NASDAQ:AHPI) +71%.GAIN Capital Holdings (NYSE:GCAP) +66% on Q4 results.Co-Diagnostics (NASDAQ:CODX) +66%.Alpha Pro Tech (NYSEMKT:APT) +48% after updating on orders.AIM Immu
- 02/27/2020
|
Diagnosis: Volatility — Every Coronavirus-Related Stock That Was Halted For Trading Today
- Wall Street has been sharply attuned to coronavirus news. In fact, the extreme volatility in the market brought 24 trading halts on Thursday.
Several biotech or pharmaceutical-...
- 02/27/2020
|
Hot Topics Recap: Coronavirus
- Recap of Coronavirus stories from Business Wire
- 02/21/2020
|
Hot Topics Recap: Coronavirus
- Recap of stories on Business Wire related to Coronavirus
- 02/14/2020
|
7 Tracking Technologies for Supply Chain Transparency
- On our first road trip to San Francisco we headed straight to Haight-Ashbury, the birthplace of 1960s counterculture and one of the most iconic landmarks in the city. We were hoping to score some LSD, and within about five minutes of arriving at the famed intersection we bought a sheet of acid from the first hippy we could find. And, just in case, we also scored psychedelics from a Rastafarian dude a couple of blocks away. Tabs on tongue, we went to explore the Bay Area. An hour passed, then two. Nothing. We tried the second batch with a similar
- 12/17/2019
|
